Komplementinhibitoren: neue Therapeutika – neue Indikationen
- 1 May 2021
- journal article
- research article
- Published by Georg Thieme Verlag KG in Transfusionsmedizin
- Vol. 11 (02) , 84-99
Abstract
Das Komplementsystem, ein klassisch transfusionsmedizinisches Thema, hat in den letzten Jahren in allen Bereichen der Medizin an Bedeutung gewonnen. Komplementinhibitoren werden aufgrund eines besseren Verständnisses der Pathophysiologie unterschiedlicher Erkrankungen in einem sich stetig erweiternden Krankheitsspektrum eingesetzt. Dieses reicht von typisch komplementassoziierten Erkrankungen wie der PNH (paroxysmale nächtliche Hämoglobinurie) bis hin zu akuten Krankheitsbildern mit einer Fehlregulation des Komplementsystems, wie COVID-19. The complement system, a classical transfusion medicine topic, has gained importance in all areas of medicine in recent years. Complement inhibitors are used in a constantly expanding spectrum of diseases due to a better understanding of the pathophysiology of different diseases. This ranges from typical complement-associated diseases such as PNH (paroxysmal nocturnal hemoglobinuria) to acute clinical pictures with a dysregulation of the complement system, such as COVID-19. Publication Date: 01 June 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyKeywords
This publication has 92 references indexed in Scilit:
- EculizumabDrugs, 2011
- Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseasesBlood, 2011
- Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytesAnnals of Hematology, 2011
- Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuriaBritish Journal of Haematology, 2010
- Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonizationHaematologica, 2010
- Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumabHaematologica, 2010
- Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split productsThe Journal of Maternal-Fetal & Neonatal Medicine, 2009
- Complement-Derived Anaphylatoxin C3a Regulates In Vitro Differentiation and Migration of Neural Progenitor CellsStem Cells, 2009
- Paroxysmal nocturnal hemoglobinuria: an acquired X-linked genetic disease with somatic-cell mosaicismCurrent Opinion in Genetics & Development, 2006
- Human complement regulator expression by the normal female reproductive tractThe Anatomical Record, 1996